As with KRAS-mutant-NSCLC, oncogenic Ras/Raf/MEK/ERK signaling upregulates PD-L1 expression in NSCLC with EGFR mutation and ALK fusion [74,75]. The gene discussed is MAPK1; the disease is non-small cell lung carcinoma.